TrialJournal of the European Academy of Dermatology and Venereology : JEADV2019

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.

A R J V Vossen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.